The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. The new funding is expected to save lives and help thousands of Australians, especially those living with melanoma. Hopefully this will ensure more government support over the next few years for MIA research.
The Government will distribute more than $400 million from the Medical Research Future Fund (MRFF) for health and medical research over the next four years, beginning with an initial disbursement of $10 million in 2015-16.
The MRFF fund has come at the best time to deliver renewed confidence to the health and medical research sector. Within a decade there will be a doubling of funding for medical research via a safe-guarded future fund while giving some immediate relief through an initial $10 million disbursement, and another $407 million to come.
“With an ageing population and more than seven million Australians already living with chronic illnesses such as cardiovascular disease, cancer and mental health issues, we cannot afford not to invest in health and medical research to find new ways to diagnose, treat and prevent these debilitating diseases,” said Association of Australian Medical Research Institutes (AAMRI) President, Professor Doug Hilton.
Professor Hilton said that health and medical research supported by the MRFF would not only improve life expectancy and quality of life for Australians, it would also deliver financial returns to the nation.
“Every dollar invested in health and medical research generates more than two dollars in health and productivity gains by reducing the burden of disease on the health system and productivity, and through the creation of new innovative businesses and jobs in the health industry,” he said.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.